A 52-year-old woman presents with a 6-week history of symmetrical polyarthritis affecting her hands, wrists, and knees. Morning stiffness lasts 2 hours. On examination, she has soft tissue swelling over the PIP and MCP joints bilaterally. Laboratory investigations show: ESR 68 mm/hr, CRP 45 mg/L, RF 280 IU/mL (positive), anti-CCP antibodies 95 U/mL (positive). Plain radiographs of hands show periarticular osteopenia but no erosions. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient presents with early, seropositive (RF and anti-CCP positive), active rheumatoid arthritis (RA) with no radiographic erosions yet—a window of opportunity for disease-modifying therapy. ## Rationale for Correct Answer **Key Point:** Early, aggressive DMARD initiation within 3 months of symptom onset is the standard of care in RA and significantly improves long-term outcomes and prevents joint damage. The correct next step is to start a conventional synthetic DMARD (csDMARD) such as methotrexate, combined with: - Short-term corticosteroids (prednisolone 10–15 mg daily, tapered over 8–12 weeks) for rapid anti-inflammatory effect - NSAIDs for symptomatic relief This "treat-to-target" approach, aiming for remission or low disease activity, is endorsed by ACR/EULAR guidelines and is the standard first-line strategy in early RA. ## Why Not the Other Options **High-Yield:** Monotherapy with corticosteroids alone (option 1) is inadequate—steroids do not modify disease progression and are used only as a bridge therapy alongside DMARDs. **Clinical Pearl:** Arthrocentesis (option 3) is not needed to confirm RA diagnosis when serology (RF, anti-CCP) and clinical presentation are already diagnostic. It may be used to exclude other conditions (infection, crystal arthropathy) if diagnosis is unclear, but it is not the next step here. Biologic therapy (option 4) is reserved for: - Inadequate response to csDMARD monotherapy or combination therapy - High disease activity despite conventional therapy - Poor prognostic factors (high RF/anti-CCP, early erosions) It is not first-line in early RA without prior csDMARD trial. ## Treatment Algorithm ```mermaid flowchart TD A[Early RA diagnosed<br/>RF/anti-CCP positive<br/>No erosions]:::outcome --> B[Start csDMARD<br/>+ prednisolone taper<br/>+ NSAIDs]:::action B --> C{Remission or<br/>low disease activity<br/>at 3 months?}:::decision C -->|Yes| D[Continue csDMARD<br/>Monitor quarterly]:::action C -->|No| E[Add second csDMARD<br/>or switch to biologic]:::action E --> F{Response?}:::decision F -->|Yes| G[Maintain therapy]:::action F -->|No| H[Escalate to biologic<br/>or combination therapy]:::action ``` **Mnemonic:** **TREAT** = **T**arget remission, **R**apid DMARD initiation, **E**arly intervention, **A**ggressive dosing, **T**herapy adjustment.